NCT04876924View on ClinicalTrials.gov

A Study of BBP-711 (ORF-229) in Healthy Adult Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

92

Participants

Timeline

Start Date

April 29, 2021

Primary Completion Date

February 27, 2022

Study Completion Date

February 27, 2022

Conditions

Healthy

Interventions

DRUG

BBP-711

BBP-711, oral suspension

DRUG

Placebo

Placebo matching BBP-711

Trial Locations (1)

85283

Celerion, Tempe

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Celerion

INDUSTRY

lead

Cantero Therapeutics, a BridgeBio company

INDUSTRY